article Open AccessTop 1% cited
Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
Allergy · 2019 · Vol. 75(5) · pp. 1188–1204
Audrey Le Floc’h(Regeneron (United States))Jeanne Allinne(Regeneron (United States))Kirsten Nagashima(Regeneron (United States))George Scott(Regeneron (United States))Dylan Birchard(Regeneron (United States))Seblewongel Asrat(Regeneron (United States))Yu Bai(Regeneron (United States))Wei Keat Lim(Regeneron (United States))Joel Martin(Regeneron (United States))Tammy Huang(Regeneron (United States))Terra Potocky(Regeneron (United States))Jeeho Kim(Regeneron (United States))Ashique Rafique(Regeneron (United States))Nicholas Papadopoulos(Regeneron (United States))Neil Stahl(Regeneron (United States))George D. Yancopoulos(Regeneron (United States))Andrew Murphy(Regeneron (United States))Matthew A. Sleeman(Regeneron (United States))Jamie Orengo✉(Regeneron (United States))
Abstract
Overall, these data support IL-4 and IL-13 as key drivers of type 2 inflammation and help provide insight into the therapeutic mechanism of dupilumab, a dual IL-4/IL-13 blocker, in multiple type 2 diseases.
Asthma and respiratory diseasesIL-33, ST2, and ILC PathwaysDermatology and Skin DiseasesDupilumabImmunologyEosinophilMedicineInterleukin 13House dust miteInflammationCytokineInterleukin 17Chemokine
MeSH terms
AnimalsInflammationInterleukin-4Interleukin-13MiceAntibodies, Monoclonal, Humanized
Funding
- Sanofi
- Regeneron Pharmaceuticals
Citations
458
FWCI
17.62
field-weighted impact
References
70
Percentile
100%
vs. same field & year
Citations per year
Cited by
Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
Allergy · 2019 · 458 citations
Type 2 immunity in the skin and lungs
Allergy · 2020 · 534 citations
References
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
European Respiratory Journal · 2001 · 826 citations
IgE, mast cells, basophils, and eosinophils
Journal of Allergy and Clinical Immunology · 2010 · 1,639 citations
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
Journal of Allergy and Clinical Immunology · 2001 · 1,287 citations
Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
Allergy · 2019 · 458 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.